Cargando…

Targeted Strategy in Lipid-Lowering Therapy

Dyslipidemia is characterized by a diminished lipid profile, including increased level of total cholesterol and low-density lipoprotein cholesterol (LDL-c) and reduced level of high-density lipoprotein cholesterol (HDL-c). Lipid-lowering agents represent an efficient tool for the prevention or reduc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dayar, Ezgi, Pechanova, Olga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138651/ https://www.ncbi.nlm.nih.gov/pubmed/35625827 http://dx.doi.org/10.3390/biomedicines10051090

Ejemplares similares

Therapeutic Potential of Polyphenols-Loaded Polymeric Nanoparticles in Cardiovascular System
por: Pechanova, Olga, et al.
Publicado: (2020)

Beneficial Effects of Cornelian Cherries on Lipid Profile and NO/ROS Balance in Obese Zucker Rats: Comparison with CoQ10
por: Dayar, Ezgi, et al.
Publicado: (2020)

Antioxidant Effect of Lonicera caerulea L. in the Cardiovascular System of Obese Zucker Rats
por: Dayar, Ezgi, et al.
Publicado: (2021)

The Future of Lipid-Lowering Therapy
por: van Zwol, Willemien, et al.
Publicado: (2019)

Nonadherence to lipid‐lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
por: Desai, Nihar R., et al.
Publicado: (2022)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
por: Kosmas, Constantine E, et al.
Publicado: (2017)

Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy
por: Sosnowska, Bożena, et al.
Publicado: (2022)

Maize-Pathogen Interactions: An Ongoing Combat from a Proteomics Perspective
por: Pechanova, Olga, et al.
Publicado: (2015)

Protective Effects of Polyphenols against Ischemia/Reperfusion Injury
por: Cebova, Martina, et al.
Publicado: (2020)

Lipid-lowering therapy: who can benefit?
por: Lewis, Sandra J
Publicado: (2011)

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Effect of Combined Antihypertensive and Lipid-Lowering Therapies on Cognitive Function: A New Treatment Strategy?
por: Kuang, Ze-Min
Publicado: (2020)

Age-Related Cognitive Impairment as a Sign of Geriatric Neurocardiovascular Interactions: May Polyphenols Play a Protective Role?
por: Jagla, Fedor, et al.
Publicado: (2015)

Role of Colesevelam in Combination Lipid-Lowering Therapy
por: Jones, Michael R., et al.
Publicado: (2013)

Role of Lipid-Lowering Therapy in Peripheral Artery Disease
por: Belur, Agastya D., et al.
Publicado: (2022)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
por: Hindi, Nagham N., et al.
Publicado: (2021)

Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges
por: Gianazza, Erica, et al.
Publicado: (2023)

Peripheral and Central Effects of Melatonin on Blood Pressure Regulation
por: Pechanova, Olga, et al.
Publicado: (2014)

Combined Therapy with Simvastatin- and Coenzyme-Q10-Loaded Nanoparticles Upregulates the Akt-eNOS Pathway in Experimental Metabolic Syndrome
por: Şaman, Ezgi, et al.
Publicado: (2022)

New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease
por: Burger, Achim Leo, et al.
Publicado: (2022)

Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values
por: Rosenson, Robert S., et al.
Publicado: (2013)

Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension
por: Kruzliak, Peter, et al.
Publicado: (2012)

Why We Still Need Reliable Animal Models
por: Pechanova, Olga
Publicado: (2020)

Nano targeted Therapies Made of Lipids and Polymers have Promising Strategy for the Treatment of Lung Cancer
por: Essa, Marwa Labib, et al.
Publicado: (2020)

Is there a role of lipid-lowering therapies in the management of fatty liver disease?
por: Tzanaki, Ismini, et al.
Publicado: (2022)

PCSK9 inhibitors: A new era of lipid lowering therapy
por: Chaudhary, Rahul, et al.
Publicado: (2017)

Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
por: Rakocevic, Jelena, et al.
Publicado: (2023)

Bridging the Racial Disparity Gap in Lipid‐Lowering Therapy
por: Kalra, Dinesh K.
Publicado: (2020)

Evolving targets for lipid-modifying therapy
por: Do, Rose Q, et al.
Publicado: (2014)

Lipid-lowering therapy in older persons
por: Aronow, Wilbert S.
Publicado: (2015)

siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy
por: Hu, Bo, et al.
Publicado: (2023)

Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
por: Rossi, Maddalena, et al.
Publicado: (2021)

Kronecker modeling and analysis of multidimensional Markovian systems
por: Dayar, Tuğrul
Publicado: (2018)

Analyzing Markov Chains using Kronecker Products: Theory and Applications
por: Dayar, Tuğrul
Publicado: (2012)

Lipids as Targets for Renal Cell Carcinoma Therapy
por: Stepanovska Tanturovska, Bisera, et al.
Publicado: (2023)

Huntingtin Lowering Strategies
por: Marxreiter, Franz, et al.
Publicado: (2020)

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?
por: Temporelli, Pier Luigi, et al.
Publicado: (2021)

Effects of Lipid Lowering Therapies on Vulnerable Plaque Features: An Updated Narrative Review of the Literature
por: Biccirè, Flavio Giuseppe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5aad9cm0hnp243b7fiv4746s4s